CD19 and neoplasm: Consistent with some data reported on NHL patients treated with anti-CD19 CAR-T cells,7,20 the best response to tandem CAR-T cell treatment was independent of the features of the patient’s previous treatment (number of lines of treatment, treatment resistance or relapse), tumour Ki67 expression and gene mutation (Supplementary Fig. S1).